Compare Gilead Sciences, Inc. (GILD) vs Wells Fargo & Co (WFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Wells Fargo & Co — how do they compare? Gilead Sciences, Inc. trades at $133.61 (market cap $163.51B), while Wells Fargo & Co trades at $88.28 (market cap $265.03B). The key difference: Wells Fargo & Co is the larger of the two by market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | WFC | |
|---|---|---|
Market Cap | $163.51B | $265.03B |
Sector | Health | Financials |
52-Week High | $155.80 | $96.40 |
52-Week Low | $108.22 | $73.42 |
Enterprise Value | $178.05B | — |
Dividend Yield | 2.49% | 2.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Wells Fargo (WFC) trades at $88.125, up 3.04% today, with a bullish technical signal and strong Q2 2026 earnings beat. The stock shows improving fundamentals with net income margin at 25.97% and a P/E of 12.72, supported by recent dividend payments and growth initiatives. News highlights robust earnings season performance and AI investments in wealth management.
Outlook remains positive with analyst consensus price target of $97.36, though risks include net interest margin pressure and volatile cash flows. Upside potential exists from loan growth and efficiency gains, but investors should monitor expense trends and economic conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Wells Fargo & Co
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →
